FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2731683048> ?p ?o ?g. }

• W2731683048 abstract "One of the innovative aspects of anti-cancer therapies is the possibility of preventing tumor growth by blocking blood supply. Cancer cells induce the formation of their own blood vessels from pre-existing vasculature, a process called angiogenesis. One of the most important proangiogenic factors is vascular endothelial growth factor (VEGF). The success of bevacizumab (a humanized anti-VEGF monoclonal antibody) combined to chemotherapy for the treatment of human metastatic cancers has validated VEGF as an efficient target. However, despite the initial enthusiasm, resistance to these anti-angiogenic treatments resulting from compensatory mechanisms occurs upon time. For this reason, there is a real need for new anti-angiogenic drugs that will target the angiogenic process through distinct mechanisms. In 2010, our laboratory has successfully developed an anti-angiogenic and anti-tumoral therapy based on destabilization of short-lived mRNAs by the zinc finger protein TIS11b. However, the therapeutic protein was highly unstable, thus making it difficult to further characterize the experimental therapy. In this context, the main task of my thesis was the optimization of TIS11b stability and activity followed by the evaluation of the multi-target action of our novel protein on tumor development. In a first part of this work, biochemical and molecular approaches allowed us to demonstrate that phosphorylation of the C-terminal serine S334 in TIS11b protein markedly increases its stability. In addition, deletion of the N-terminal domain of TIS11b highly increases its protein stability without affecting its activity. Therefore, we integrated N-terminal truncation (ZnC) and C-terminal substitution of S334 by an aspartate to mimic a permanent phosphorylation at S334 (ZnCS334D) as a novel TIS11b engineering strategy. Both proteins were fused subsequently to a cell-penetrating peptide polyarginine (R9). In vitro studies revealed that R9-ZnC and R9-ZnCS334D inhibit VEGF expression in the murine breast cancer cells 4T1. In addition, R9-ZnCS334D impaired proliferation, migration, invasion and anchorage-independent growth of 4T1 cells. In vivo, intra-tumoral injection of either protein significantly reduced VEGF expression and tumor vascularization. Strikingly, antibody array analyses of tumor extracts demonstrated a reduced expression of several chemokines such as Fractalkine, MCP-1, NOV, SDF-1 and Pentraxin upon R9-ZnC or R9-ZnCS334D treatment. These factors, which are produced by several cell types within tumor tissue, are key drivers of tumor angiogenesis, tumor-promoting inflammation and invasion. Furthermore, the expression of markers of the epithelial-to-mesenchymal transition was also significantly reduced, suggesting an anti-metastatic effect of R9-ZnC and R9-ZnCS334D. Thus, we provide R9-ZnC and R9-ZnCS334D as potential novel multi-target agents which inhibit key hallmarks of cancer progression. This work supports the emerging link between mRNA stability and cancer and proposes novel concepts for the development of innovative anti-cancer therapies." @default.
• W2731683048 created "2017-07-14" @default.
• W2731683048 creator A5013500913 @default.
• W2731683048 date "2014-12-12" @default.
• W2731683048 modified "2023-09-23" @default.
• W2731683048 title "A novel multi-target cancer therapy based on destabilization of short-lived mRNAs" @default.
• W2731683048 hasPublicationYear "2014" @default.
• W2731683048 type Work @default.
• W2731683048 sameAs 2731683048 @default.
• W2731683048 citedByCount "0" @default.
• W2731683048 crossrefType "dissertation" @default.
• W2731683048 hasAuthorship W2731683048A5013500913 @default.
• W2731683048 hasConcept C121608353 @default.
• W2731683048 hasConcept C126322002 @default.
• W2731683048 hasConcept C151730666 @default.
• W2731683048 hasConcept C167734588 @default.
• W2731683048 hasConcept C2776694085 @default.
• W2731683048 hasConcept C2777025900 @default.
• W2731683048 hasConcept C2777802072 @default.
• W2731683048 hasConcept C2779343474 @default.
• W2731683048 hasConcept C2780394083 @default.
• W2731683048 hasConcept C502942594 @default.
• W2731683048 hasConcept C71924100 @default.
• W2731683048 hasConcept C86803240 @default.
• W2731683048 hasConcept C96232424 @default.
• W2731683048 hasConceptScore W2731683048C121608353 @default.
• W2731683048 hasConceptScore W2731683048C126322002 @default.
• W2731683048 hasConceptScore W2731683048C151730666 @default.
• W2731683048 hasConceptScore W2731683048C167734588 @default.
• W2731683048 hasConceptScore W2731683048C2776694085 @default.
• W2731683048 hasConceptScore W2731683048C2777025900 @default.
• W2731683048 hasConceptScore W2731683048C2777802072 @default.
• W2731683048 hasConceptScore W2731683048C2779343474 @default.
• W2731683048 hasConceptScore W2731683048C2780394083 @default.
• W2731683048 hasConceptScore W2731683048C502942594 @default.
• W2731683048 hasConceptScore W2731683048C71924100 @default.
• W2731683048 hasConceptScore W2731683048C86803240 @default.
• W2731683048 hasConceptScore W2731683048C96232424 @default.
• W2731683048 hasLocation W27316830481 @default.
• W2731683048 hasOpenAccess W2731683048 @default.
• W2731683048 hasPrimaryLocation W27316830481 @default.
• W2731683048 hasRelatedWork W1969462363 @default.
• W2731683048 hasRelatedWork W2022501871 @default.
• W2731683048 hasRelatedWork W2146800298 @default.
• W2731683048 hasRelatedWork W2148844734 @default.
• W2731683048 hasRelatedWork W2151365383 @default.
• W2731683048 hasRelatedWork W2318314586 @default.
• W2731683048 hasRelatedWork W2606875972 @default.
• W2731683048 hasRelatedWork W2766579064 @default.
• W2731683048 hasRelatedWork W2769028289 @default.
• W2731683048 hasRelatedWork W2890124177 @default.
• W2731683048 hasRelatedWork W2893671125 @default.
• W2731683048 hasRelatedWork W2915626948 @default.
• W2731683048 hasRelatedWork W2994980331 @default.
• W2731683048 hasRelatedWork W3126202503 @default.
• W2731683048 hasRelatedWork W3206555153 @default.
• W2731683048 hasRelatedWork W2244029314 @default.
• W2731683048 hasRelatedWork W2344952581 @default.
• W2731683048 hasRelatedWork W2466867603 @default.
• W2731683048 hasRelatedWork W2736639022 @default.
• W2731683048 hasRelatedWork W2876814127 @default.
• W2731683048 isParatext "false" @default.
• W2731683048 isRetracted "false" @default.
• W2731683048 magId "2731683048" @default.
• W2731683048 workType "dissertation" @default.